Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) - Poseida

Skip to content

Technology
Pipeline
Clinical Trials
Publications Archive
News Archive
Careers

American Society of Hematology Annual Meeting (ASH) 2020

<img width="201" height="38" src="https://poseida.com/wp-content/uploads/2023/03/poseida-logo-white.png" class="image wp-image-92 attachment-full size-full" alt="“Poseida” Therapeutics - Bold solutions with the Capacity to Cure" style="max-width: 100%; height: auto;" decoding="async" />

Poseida Therapeutics, Inc.
A Member of the Roche Group
9390 Towne Centre Drive Suite 200
San Diego, CA 92121
info@poseida.com

Privacy Policy
Expanded Access Policy
Accessibility Statement

© 2025 Poseida Therapeutics, Inc. | All rights reserved.

<img width="201" height="38" src="https://poseida.com/wp-content/uploads/2023/03/poseida-logo-white.png" class="image wp-image-92 attachment-full size-full" alt="“Poseida” Therapeutics - Bold solutions with the Capacity to Cure" style="max-width: 100%; height: auto;" decoding="async" />

Poseida Therapeutics, Inc.
A Member of the Roche Group
9390 Towne Centre Drive Suite 200
San Diego, CA 92121
info@poseida.com

© 2025 Poseida Therapeutics, Inc.
All rights reserved.

Privacy Policy
Expanded Access Policy
Accessibility Statement